Acadia Pharmaceuticals Inc.
Mark C. Schneyer (EVP, CHIEF FINANCIAL OFFICER) sells ACAD shares
About this filing
Acadia Pharmaceuticals Inc. (ACAD) filed Form 4 (insider transaction) with the SEC on Oct 30, 2026. Form 4 reports a company insider’s trades in the company’s shares.
Key facts
- Insider
- Mark C. Schneyer · EVP, CHIEF FINANCIAL OFFICER
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Oct 15, 2026 | A · grantFootnotes F1 | +6,815 | $0.00 | $0.00 | 74,643 | Direct |
| Oct 30, 2026 | S · open-market saleFootnotes F2 | −3,321 | $20.88 | $69,342.48 | 71,322 | Direct |
Footnotes
- F1 Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at incremental 25% of target. Together with the vesting on August 16, 2024 and September 12, 2025, the performance stock units have vested at 100% of target.
- F2 The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
More ACAD filings
- 8-K
Filed Oct 23, 2026
- 8-K
Filed Sep 24, 2026
- 8-K
Filed Sep 11, 2026
- 4
Filed Aug 7, 2026
- SC 13G
Filed Aug 7, 2026
- 144
Filed Aug 5, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.